MedTrace Logo

Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

NCT05279924 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-10-26

No results posted yet for this study

Summary

Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast

Conditions

Interventions

DRUG

Prophylaxis with Emicizumab

Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • N'Dogomo Meité, MD · CHU de Cocody

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-10-20
Completion
2022-10-20

Countries

  • Côte d’Ivoire

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05279924 on ClinicalTrials.gov